89bio Stock Price, News & Analysis (NASDAQ:ETNB) $9.86 -0.09 (-0.90%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$9.60▼$10.0150-Day Range$6.66▼$16.0352-Week Range$6.57▼$22.93Volume1.70 million shsAverage Volume1.58 million shsMarket Capitalization$745.80 millionP/E RatioN/ADividend YieldN/APrice Target$32.89 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media 89bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside233.6% Upside$32.89 Price TargetShort InterestBearish7.99% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.09) to ($2.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.57 out of 5 starsMedical Sector841st out of 954 stocksPharmaceutical Preparations Industry322nd out of 362 stocks 3.4 Analyst's Opinion Consensus Rating89bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.89, 89bio has a forecasted upside of 233.6% from its current price of $9.86.Amount of Analyst Coverage89bio has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.99% of the outstanding shares of 89bio have been sold short.Short Interest Ratio / Days to Cover89bio has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 89bio has recently increased by 11.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yield89bio does not currently pay a dividend.Dividend Growth89bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ETNB. Previous Next 1.9 News and Social Media Coverage News Sentiment89bio has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for 89bio this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for ETNB on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added 89bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 89bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of 89bio is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 89bio are expected to decrease in the coming year, from ($2.09) to ($2.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 89bio is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 89bio is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio89bio has a P/B Ratio of 3.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 89bio Stock (NASDAQ:ETNB)89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.Read More ETNB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETNB Stock News HeadlinesDecember 7, 2023 | markets.businessinsider.comBuy Rating Affirmed for 89bio Amid Promising NASH Drug DevelopmentsDecember 7, 2023 | markets.businessinsider.comBuy Rating Affirmed for 89bio Amid Promising NASH Drug DevelopmentsDecember 9, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 7, 2023 | markets.businessinsider.com89bio Prices Offering Of 15.135 Mln Shares At $9.25/shr; Stock Down In Pre-marketDecember 7, 2023 | msn.com89bio stock dips on upsized pricing of $150.0 million securities offeringDecember 7, 2023 | tmcnet.com89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded WarrantsDecember 7, 2023 | finance.yahoo.com89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded WarrantsDecember 6, 2023 | finance.yahoo.com89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsDecember 9, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 6, 2023 | seekingalpha.com89bio: Despite Peer Trial Setback, Potential Remains In NASHDecember 6, 2023 | americanbankingnews.com89bio's (ETNB) "Buy" Rating Reaffirmed at HC WainwrightDecember 5, 2023 | benzinga.com89bio Stock (NASDAQ:ETNB), Analyst Ratings, Price Targets, PredictionsDecember 5, 2023 | markets.businessinsider.comOptimistic Buy Rating for 89bio on Pegozafermin’s Strategic Regulatory Alignment and Cost EfficienciesDecember 4, 2023 | markets.businessinsider.com89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver DiseaseDecember 4, 2023 | msn.com89bio aligns with regulators on Phase 3 trials for NASH candidateNovember 29, 2023 | markets.businessinsider.comBuy Recommendation for 89bio’s Pegozafermin Based on Positive Phase 2b Results and Strong Safety ProfileNovember 29, 2023 | americanbankingnews.com89bio (NASDAQ:ETNB) Receives "Buy" Rating from HC WainwrightNovember 29, 2023 | markets.businessinsider.comSustained Efficacy and Safety of Pegozafermin Reinforce Buy Rating for 89bio’s Stock (ETNB)November 27, 2023 | markets.businessinsider.com89bio's Fatty Liver Candidate Shows Long-Term Improvement: DetailsNovember 27, 2023 | markets.businessinsider.com89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)November 21, 2023 | finance.yahoo.com89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx ConferenceNovember 12, 2023 | finance.yahoo.com89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023November 10, 2023 | markets.businessinsider.comBuy Rating for 89bio: Promising Pipeline Developments and Pegozafermin’s Breakthrough for NASH TreatmentNovember 9, 2023 | finance.yahoo.com89bio Inc (ETNB) Reports Increased R&D and G&A Expenses in Q3 2023November 8, 2023 | tmcnet.com89bio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesOctober 26, 2023 | seekingalpha.com89bio's Low Price Presents An OpportunityOctober 26, 2023 | seekingalpha.com89bio: Risk And Reward Balance In NASH TherapeuticsSee More Headlines Receive ETNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ETNB CUSIPN/A CIK1785173 Webwww.89bio.com Phone415-432-9270FaxN/AEmployees45Year FoundedN/APrice Target and Rating Average Stock Price Target$32.89 High Stock Price Target$50.00 Low Stock Price Target$24.00 Potential Upside/Downside+233.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.92% Return on Assets-30.80% Debt Debt-to-Equity Ratio0.06 Current Ratio18.23 Quick Ratio18.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book3.29Miscellaneous Outstanding Shares75,639,000Free Float72,311,000Market Cap$745.80 million OptionableNot Optionable Beta0.89 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Rohan Palekar (Age 57)CEO & Director Comp: $990.52kMr. Quoc Le-Nguyen (Age 55)Chief Technical Operations Officer & Head of Quality Comp: $654.44kDr. Harry Mansbach M.D. (Age 58)Chief Medical Officer Comp: $691.87kMr. Ryan Stephen Martins (Age 45)Chief Financial Officer Mr. Shiva K. Natarajan (Age 57)Senior Vice President of Finance & Principal Accounting Officer Ms. Melissa AbelSenior Vice President of Commercial Strategy & CommunicationsMs. Amanda KuriharaVice President of People & CultureMs. Yun BaiVP & Head of CMCMr. Paul ShinSenior Vice President of R&D OperationsMr. Michael BaldwinVP & Head of QualityMore ExecutivesKey CompetitorsPharming GroupNASDAQ:PHARVerve TherapeuticsNASDAQ:VERVCogent BiosciencesNASDAQ:COGTTango TherapeuticsNASDAQ:TNGXDyne TherapeuticsNYSE:DYNView All CompetitorsInsiders & InstitutionsHudson Bay Capital Management LPBought 65,500 shares on 12/7/2023Ownership: 0.000%Citigroup Inc.Bought 27,294 shares on 12/6/2023Ownership: 0.214%Deutsche Bank AGSold 771,532 shares on 11/24/2023Ownership: 0.043%Walleye Capital LLCBought 38,266 shares on 11/21/2023Ownership: 0.113%Wolverine Trading LLCBought 10,600 shares on 11/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ETNB Stock Analysis - Frequently Asked Questions Should I buy or sell 89bio stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ETNB shares. View ETNB analyst ratings or view top-rated stocks. What is 89bio's stock price target for 2024? 6 brokers have issued 12-month target prices for 89bio's stock. Their ETNB share price targets range from $24.00 to $50.00. On average, they expect the company's share price to reach $32.89 in the next twelve months. This suggests a possible upside of 233.6% from the stock's current price. View analysts price targets for ETNB or view top-rated stocks among Wall Street analysts. How have ETNB shares performed in 2023? 89bio's stock was trading at $12.73 at the beginning of the year. Since then, ETNB stock has decreased by 22.5% and is now trading at $9.86. View the best growth stocks for 2023 here. Are investors shorting 89bio? 89bio saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 6,040,000 shares, an increase of 11.2% from the October 31st total of 5,430,000 shares. Based on an average daily volume of 1,550,000 shares, the days-to-cover ratio is currently 3.9 days. View 89bio's Short Interest. When is 89bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 8th 2024. View our ETNB earnings forecast. How were 89bio's earnings last quarter? 89bio, Inc. (NASDAQ:ETNB) issued its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.08. The firm earned $1 million during the quarter, compared to analyst estimates of $0.38 million. 89bio's revenue for the quarter was up .0% on a year-over-year basis. What ETFs hold 89bio's stock? ETFs with the largest weight of 89bio (NASDAQ:ETNB) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Invesco DWA SmallCap Momentum ETF (DWAS), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC) and Harbor Health Care ETF (MEDI).iShares Micro-Cap ETF (IWC). What other stocks do shareholders of 89bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO). When did 89bio IPO? (ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager. Who are 89bio's major shareholders? 89bio's stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (2.82%), Adage Capital Partners GP L.L.C. (2.25%), Braidwell LP (2.11%), Westfield Capital Management Co. LP (1.74%), Laurion Capital Management LP (1.59%) and Eagle Asset Management Inc. (0.94%). Insiders that own company stock include Edward Morrow Atkinson III, Gregory Grunberg, Kathleen Laporte, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins. View institutional ownership trends. How do I buy shares of 89bio? Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ETNB) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.